Comparison · NCT00686920-sae
New Rifaximin vs Continuing Rifaximin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. New Rifaximin vs Continuing Rifaximin: serious adverse events. Trial comparisons, record NCT00686920-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00686920-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.627 | 0.566 | 0.684 | wilson | |
| Risk in group 2 | 0.7 | 0.585 | 0.795 | wilson | |
| Risk difference, group 1 minus group 2 | -0.073 | -0.186 | 0.0559 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.896 | 0.748 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.72 | 0.407 | 1.28 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on New Rifaximin than on Continuing Rifaximin | 13.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | New Rifaximin | Participants new to receiving rifaximin were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study. | 158 | 252 | EG000 |
| Group 2 | Continuing Rifaximin | Participants who received rifaximin in the previous rifaximin HE study were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study. | 49 | 70 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to Month 36
Source ClinicalTrials.gov
Trial
- Title
- Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
- NCT number
- NCT00686920
- Phases
- PHASE3
- Conditions
- Hepatic Encephalopathy
- Interventions
- Rifaximin
- Lead sponsor
- Bausch Health Americas, Inc.
- Results first posted
- 2019-08-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00686920?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00686920-sae